myMatrixx and Tower Premiere Webinar: A Prescription for Settling Legacy Claims

Posted on by myMatrixx
Tower MSA

As claims age, the percentage of spend for prescription drugs increases. Further, as claims age, the likelihood that the injured worker becomes a Medicare beneficiary as a result of age or disability increases. The result, high prescription drug costs allocated in the Medicare Set-Aside (MSA) become a barrier to settlement of these legacy claims.

When settling claims, especially legacy claims, it is best to employ as many expert resources as possible. Your PBM’s clinical team and MSA consultant possess specialized expertise that can be used to ensure the best possible settlement outcome.

myMatrixx shares the common goal of claims resolution with our clients and manage pharmacy benefits aggressively from the date-of-injury to ensure appropriate medication usage and responsible prescribing for when the time comes to pursue a MSA settlement.

In furtherance of this goal, myMatrixx has partnered with a leading national provider of MSA settlement services, TowerMSA Partners, in which we can work directly with to bring you a hassle-free, diverse expertise-driven approach to settling claims.

To hear more about this partnership and some expert advice on settling legacy claims, please join us for a free webinar presented by Phil Walls, RPh, Chief Clinical Officer for myMatrixx, and Dan Anders, Esq., Chief Compliance Officer for TowerMSA Partners. Attendees will learn how:

  • Analytics can be used to define and quantify legacy claims
  • To identify factors driving up Rx costs
  • Data can be used to identify opportunities for clinical intervention
  • To work effectively with PBM and MSA provider to reduce Rx cost and close claims
  • Best practices in Rx management can be used to prevent legacy claims

We invite you to take advantage of this opportunity to learn how your MSA experience can be enhanced and settlements optimized.

Click here to register for the upcoming webinar on Wednesday, May 20th at 2p EST.